Accendra Health(DE:6OM)
€0.12+0.00 (+3.51%)
DE:6OM
Accendra Health earnings date
€0.12
At close:+0.00 (+3.51%)
Accendra Health (6OM) Q3 2026 Earnings Report
1 Followers
DE:6OM Q3 2026 EPS Results
- Actual EPS
- -EUR 0.21
- Consensus EPS
- EUR 0.01
- Beat/Miss
- Missed by -EUR 0.21
- One Year Ago EPS
- EUR 0.23
DE:6OM Q3 2026 Revenue Results
- Actual Revenue
- EUR 542.31M
- Expected Revenue
- EUR 557.22M
- Beat/Miss
- Missed by -EUR 14.92M
- YoY Revenue Growth
- -13.69%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
DE:6OM Upcoming Earnings
Accendra Health's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
DE:6OM Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Negative
The call had several constructive elements, including strong liquidity, debt reduction, progress on payer audits, an extended receivables facility, and a detailed turnaround plan with execution already underway. However, the overall tone was negative because third-quarter results were described as extremely disappointing, revenue declined, multiple categories remained weak, operating costs were elevated, and full-year adjusted EBITDA guidance was reduced by as much as 30% versus the prior midpoint.
Company Guidance
For the remainder of 2026, Accendra Health now believes full-year net revenue will be at the bottom of its previous guidance range of $2.45 billion-$2.55 billion, adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of the last adjusted EBITDA guidance provided, and adjusted EBITDA for Q4 is expected to be comparable to the third quarter; future CapEx will be quite a bit lower in 2027 than 2026, the company expects to share its outlook for 2027 early next year, and it expects to share further details, including expectations on the financial impact of the changes, in Q1 of 2027.
- Strong Liquidity and Cash ManagementManagement said liquidity remains strong, with $27 million of cash, only $35 million drawn on the revolving credit facility, and nearly $300 million of available liquidity sources as of September 30. The company expects to have plenty of liquidity for the foreseeable future.
- Debt Reduction and Covenant ComplianceNet debt was $1.73 billion, down $40 million versus December 31, while total debt for the year was down $295 million following the year-end 2025 divestiture and June balance sheet optimization transactions. The company remains in compliance with its quarterly debt covenants.
- Working Capital Provided Cash FlowChanges in receivables, payables, and inventory provided approximately $24 million of cash flow in the third quarter and $7 million for the nine months ended September 30.
- Extended Accounts Receivable Securitization FacilityAccendra extended its accounts receivable securitization facility by two years beyond the last maturity date. The facility is now available until October 2029, remains sized at $150 million, and management said the extension further supports liquidity.
- Payer Audit Resolution ProgressManagement said the payer audits are largely behind the company. Accendra reached an agreement allowing a major payer to sample prepay audits, passed those audits with flying colors, and began receiving the expected cash during the third quarter. Management expects the remaining work to wrap up in the fourth quarter, with no expected impact extending into 2027.
- Improvement in Contractual AllowancesThe third-quarter contractual allowance impact was $6 million favorable versus the prior year, an improvement from the approximately $10 million cited in each of the first and second quarters. The third-quarter impact was about $4 million smaller than in the previous two quarters.
- Sleep and Soft Goods Category GrowthExcluding the terminated large commercial payer contract and the sale of a non-core asset, sleep revenue grew over 4%, primarily driven by sleep supplies. The soft goods group of ostomy, urology, and incontinence also grew, although at a slower rate than earlier in the year.
- Lower Future Capital Expenditure BurdenManagement said $35 million of year-to-date 2026 patient service equipment CapEx related to the former large commercial payer contract, with disproportionately large CapEx relative to the adjusted EBITDA generated. Because the related final cash outlays are continuing into the third quarter, adjusted EBITDA less CapEx is expected to benefit meaningfully, and future CapEx is expected to be quite a bit lower in 2027 than in 2026.
- Potential Non-Core Asset ProceedsAccendra is still working toward closing the sale of a small, very non-core asset, expected to generate about $14 million in proceeds. Management expects a fourth-quarter close and said the sale will have no impact on revenue or adjusted EBITDA.
- Turnaround Plan and Execution Already UnderwayManagement has developed a forward-looking value creation plan focused on winning referrals, improving patient compliance and retention, optimizing revenue cycle management, and rebuilding the branch and back-office operating system. A dedicated transformation function has been launched with quarterly hard-dollar targets.
- Commercial and Operational ReorganizationAccendra consolidated commercial operations, including commercial contracting, under its new Chief Commercial Officer. The former Chief Operating Officer transitioned to an advisory role, and the CEO assumed direct oversight of branch and back-office operations.
- Planned Digital and Process ImprovementsThe company plans to continue scaling its Sleep Center of Excellence and accelerating adoption of end-to-end digital referral management. In the first quarter, Accendra plans to launch the first iteration of revamped branch and back-office operations, including simplified processes and automated activities.
- Runway Before Refinancing MaturityManagement said prior liquidity and balance sheet work, together with the recurring-revenue nature of the business, provides the runway needed to execute the changes before the company needs to refinance its first maturity in early 2029.
- Improved Investor Reporting PlannedBeginning in the fourth quarter and into 2027, Accendra plans to enhance reporting to improve transparency, align stakeholders with management metrics, and simplify the investment thesis.
DE:6OM Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | 0.01- | 0.19 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | 0.01-0.21 | 0.23 | -192.00% (-0.43) | |
| Aug 10, 2026 | 2026 (Q2) | -0.08-0.17 | 0.23 | -173.08% (-0.41) | |
| May 11, 2026 | 2026 (Q1) | -0.09-0.04 | 0.21 | -117.39% (-0.24) | |
| Feb 19, 2026 | 2025 (Q4) | 0.200.19 | 0.5 | -61.82% (-0.31) | |
| Oct 30, 2025 | 2025 (Q3) | 0.210.23 | 0.38 | -40.48% (-0.15) | |
| Aug 11, 2025 | 2025 (Q2) | 0.250.23 | 0.32 | -27.78% (-0.09) | |
| May 08, 2025 | 2025 (Q1) | 0.180.21 | 0.17 | 21.05% (+0.04) | |
| Feb 28, 2025 | 2024 (Q4) | 0.470.50 | 0.62 | -20.29% (-0.13) | |
| Nov 04, 2024 | 2024 (Q3) | 0.370.38 | 0.4 | -4.55% (-0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
